Valued at a market cap of $228.3 billion, Abbott Laboratories (ABT) is a global healthcare company that discovers, develops, ...

Let’s dig into the relative performance of Abbott Laboratories (NYSE:ABT) and its peers as we unravel the now-completed Q4 ...

Abbott Laboratories closed 6.08% below its 52-week high of $141.23, which the company reached on March 4th.

Abbott’s pulse field ablation system competes with products from Medtronic and Boston Scientific, which also have large ...

Abbott Laboratories (NYSE:ABT) recently announced successful outcomes from its TRILUMINATE™ Pivotal trial for the TriClip™ system, showcasing significant improvements in patient outcomes for tricuspid ...

We recently published a list of Jim Cramer Discusses These 10 Stocks & Says US Faces Unfairly High Tariffs Abroad. In this ...

In a report released yesterday, Larry Biegelsen from Wells Fargo maintained a Buy rating on Abbott Laboratories (ABT – Research Report), with a ...

On Feb. 19, students from Roberts Middle School in Cuyahoga Falls, Ohio, toured R.D. Abbott's Barberton Service Center, which ...

Johnson & Johnson and Boston Scientific have also recently made moves to sell their own coronary intravascular lithotripsy ...

Abbott (ABT) announced late-breaking data from its Triluminate Pivotal trial that show the TriClip transcatheter edge-to-edge repair system to ...

Abbott Laboratories closed 11.07% short of its 52-week high of $141.23, which the company achieved on March 4th.

The company is first rolling out the use of the Volt system among European Union doctors who have already gained experience ...